3D Printed Drugs Market Expected to Reach $522 Million by 2030
According to a new report published by Allied Market Research, titled, 3D Printed Drugs Market, Spritam is the only 3D printed drug available in the market since 2016 to treat epilepsy. The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. U.S. market holds the highest market share in 2020.
View full press release